148 related articles for article (PubMed ID: 17618619)
1. Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2.
Riddle EL; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2007 Sep; 571(1):25-8. PubMed ID: 17618619
[TBL] [Abstract][Full Text] [Related]
2. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Neurosci; 2002 Oct; 22(19):8705-10. PubMed ID: 12351745
[TBL] [Abstract][Full Text] [Related]
3. The effect of chronic methylphenidate administration on presynaptic dopaminergic parameters in a rat model for ADHD.
Simchon Y; Weizman A; Rehavi M
Eur Neuropsychopharmacol; 2010 Oct; 20(10):714-20. PubMed ID: 20493667
[TBL] [Abstract][Full Text] [Related]
4. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
[TBL] [Abstract][Full Text] [Related]
5. Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles.
Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE
J Neurosci Methods; 2009 Feb; 177(1):177-82. PubMed ID: 18992277
[TBL] [Abstract][Full Text] [Related]
6. Methylphenidate-induced alterations in synaptic vesicle trafficking and activity.
Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE
Ann N Y Acad Sci; 2008 Oct; 1139():285-90. PubMed ID: 18991873
[TBL] [Abstract][Full Text] [Related]
7. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications.
Hanson GR; Sandoval V; Riddle E; Fleckenstein AE
Ann N Y Acad Sci; 2004 Oct; 1025():146-50. PubMed ID: 15542712
[TBL] [Abstract][Full Text] [Related]
8. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
9. Impulsive choice and environmental enrichment: effects of d-amphetamine and methylphenidate.
Perry JL; Stairs DJ; Bardo MT
Behav Brain Res; 2008 Nov; 193(1):48-54. PubMed ID: 18534693
[TBL] [Abstract][Full Text] [Related]
10. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.
Riddle EL; Topham MK; Haycock JW; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2002 Aug; 449(1-2):71-4. PubMed ID: 12163108
[TBL] [Abstract][Full Text] [Related]
11. Critical role of the embryonic mid-hindbrain organizer in the behavioral response to amphetamine and methylphenidate.
Tilleman H; Kofman O; Nashelsky L; Livneh U; Roz N; Sillaber I; Biegon A; Rehavi M; Brodski C
Neuroscience; 2009 Nov; 163(4):1012-23. PubMed ID: 19635527
[TBL] [Abstract][Full Text] [Related]
12. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
[TBL] [Abstract][Full Text] [Related]
13. Melatonin attenuates the amphetamine-induced decrease in vesicular monoamine transporter-2 expression in postnatal rat striatum.
Mukda S; Vimolratana O; Govitrapong P
Neurosci Lett; 2011 Jan; 488(2):154-7. PubMed ID: 21078367
[TBL] [Abstract][Full Text] [Related]
14. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine.
Kuczenski R; Segal DS
J Pharmacol Exp Ther; 2001 Mar; 296(3):876-83. PubMed ID: 11181919
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain.
Freyberg Z; Sonders MS; Aguilar JI; Hiranita T; Karam CS; Flores J; Pizzo AB; Zhang Y; Farino ZJ; Chen A; Martin CA; Kopajtic TA; Fei H; Hu G; Lin YY; Mosharov EV; McCabe BD; Freyberg R; Wimalasena K; Hsin LW; Sames D; Krantz DE; Katz JL; Sulzer D; Javitch JA
Nat Commun; 2016 Feb; 7():10652. PubMed ID: 26879809
[TBL] [Abstract][Full Text] [Related]
16. Action potentials and amphetamine release antipsychotic drug from dopamine neuron synaptic VMAT vesicles.
Tucker KR; Block ER; Levitan ES
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4485-94. PubMed ID: 26216995
[TBL] [Abstract][Full Text] [Related]
17. Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex.
Tan H; Young LT; Shao L; Che Y; Honer WG; Wang JF
Int J Neuropsychopharmacol; 2012 Oct; 15(9):1275-85. PubMed ID: 21939588
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of psychomotor stimulants on attentional performance in rats: nicotine, amphetamine, caffeine and methylphenidate.
Bizarro L; Patel S; Murtagh C; Stolerman IP
Behav Pharmacol; 2004 May; 15(3):195-206. PubMed ID: 15187577
[TBL] [Abstract][Full Text] [Related]
19. Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans.
Boileau I; Houle S; Rusjan PM; Furukawa Y; Wilkins D; Tong J; Selby P; Wilson AA; Kish SJ
Synapse; 2010 Jun; 64(6):417-20. PubMed ID: 20169578
[TBL] [Abstract][Full Text] [Related]
20. Neuronal development genes are key elements mediating the reinforcing effects of methamphetamine, amphetamine, and methylphenidate.
Dela Peña I; Jeon SJ; Lee E; Ryu JH; Shin CY; Noh M; Cheong JH
Psychopharmacology (Berl); 2013 Dec; 230(3):399-413. PubMed ID: 23783774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
